|
Welcome to the Nucleic Acid Diagnostics & Therapeutics Summit. This inaugural summit will be held in Boston, MA immediately prior to the annual RNAi World Congress, which will address the latest research in RNAi and microRNA research.
In contrast the DxRx Summit will be attended by investors, corporate management, business leaders, legal & regulatory advisors, clinical trial CROs and others who are interested in the diagnostic and therapeutic applications of DNA, RNAi, microRNA's and antisense technology.
Registered delegates will also be eligible to attend a half-day interactive business tutorial on the market and business landscape for diagnostics and therapeutics based on RNAi and microRNAs hosted by Enal Razvi, PhD.
Register now and save up to $200!
Call for Papers
Deadline: 10 November 2008
If you would like to be considered for an oral presentation at this meeting, submit an abstract for review now!
Agenda Topics
- Reviews of Company Pipelines
- Clinical Trial Status of Nucleic Acid-Based Therapeutics
- Patent Status of Nucleic Acid-Based Diagnostics and Therapeutics
- Nucleic Acid Drug Delivery
- microRNAs as Diagnostics and Therapeutic Entities
- Nucleic Acid Biomarkers for Personalized Medicine
- Reimbursement and Regulatory Landscape
- Investor Attitudes to this Sector
- Emerging Company Showcase
|
|
Confirmed Speakers
Dr Patrick Y. Lu,
President and CEO, Sirnaomics
Dr Dmitry Samarsky,
VP Technology Development, RXi Pharmaceuticals
Dr James Hamilton,
CEO, Calando Pharmaceuticals
Prof James G Patton,
Vanderbilt University
Jeffery Vick,
CEO, Silence Therapeutics
Dr Nobuyoshi Kosaka,
National Cancer Center Research Institute, Tokyo
Dr Nicolay Ferrari,
Director of Pharmacology, Topigen
Dr Søren Tulstrup,
CEO, Santaris Pharma
Dr William Marshall,
President and CEO, Miragen Therapeutics | |